⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL1793163 | 0.93 | — | — | |
| Pyrrolidine SCHEMBL15387295 | 0.93 | ALDH1A1 (0.50) | — | |
| Azepane SCHEMBL9998550 | 0.90 | ALDH1A1 (0.56) | — | |
| Azepane SCHEMBL29776406 | 0.90 | ALDH1A1 (0.56) | — | |
| Carbamic Acid SCHEMBL1764104 | 0.90 | SMN1; SMN2 (0.56) | — | |
| Piperidine SCHEMBL8761997 | 0.90 | ALDH1A1 (0.56) | — | |
| Piperidine SCHEMBL1793471 | 0.90 | ALDH1A1 (0.56) | — | |
| Piperidine SCHEMBL10778074 | 0.90 | ALDH1A1 (0.56) | — | |
| Carbamic Acid SCHEMBL1422618 | 0.88 | — | — | |
| Azetidine SCHEMBL19586846 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834482-B2 | Agents modulating beta-catenin functions and methods thereof | FOG PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220213154-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11214578-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-11198713-B2 | Agents modulating beta-catenin functions and methods thereof | FOG PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200148696-A1 | Urea/Carbamates FAAH MAGL Or Dual FAAH/MAGL Inhibitors And Uses Thereof | NORTHEASTERN UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| US-10570146-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3526206-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-21 | — | — | EP | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| EP-2616071-A2 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1656368-A4 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1656368-A2 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004665-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |